LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 894,337 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the transaction, the director directly owned 539,763 shares of the company’s stock, valued at approximately $5,467,799.19. This trade represents a 62.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Robert Bessler also recently made the following trade(s):

• On Tuesday, May 12th, Robert Bessler sold 575,034 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.02, for a total transaction of $4,611,772.68.
• On Thursday, May 7th, Robert Bessler sold 75,000 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.55, for a total value of $641,250.00.
• On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total value of $438,136.35.
• On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $54,264.00.
• On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total transaction of $35,758.01.

LifeStance Health Group Price Performance

Shares of NASDAQ:LFST opened at $10.74 on Wednesday. The company has a market capitalization of $4.17 billion, a PE ratio of 179.07 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a fifty day moving average of $8.06 and a 200-day moving average of $7.31. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $10.89.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company had revenue of $403.48 million during the quarter, compared to analysts’ expectations of $387.46 million. The firm’s revenue was up 21.2% on a year-over-year basis. As a group, equities analysts anticipate that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC boosted its stake in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after buying an additional 3,791 shares in the last quarter. KBC Group NV acquired a new position in LifeStance Health Group during the first quarter worth $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after acquiring an additional 5,404 shares during the period. Bayesian Capital Management LP bought a new position in shares of LifeStance Health Group during the second quarter valued at $52,000. Finally, PNC Financial Services Group Inc. boosted its stake in shares of LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after purchasing an additional 7,987 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on LFST shares. JPMorgan Chase & Co. increased their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Weiss Ratings reiterated a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. Barclays increased their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. Jefferies Financial Group upgraded LifeStance Health Group to a “strong-buy” rating in a report on Thursday, March 12th. Finally, The Goldman Sachs Group initiated coverage on LifeStance Health Group in a research report on Friday, June 5th. They issued a “neutral” rating and a $9.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.75.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.